| HEIDELBERG PHARMA AG O.N. |
| Deutschland |
| Gesundheit |
| DE000A11QVV0 / A11QVV |
| HPHA (Frankfurt) |
| FRA:HPHA, ETR:HPHA, HPHA:GR |
| - |
| https://heidelberg-pharma.. |
|
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in oncology, developing innovative antibody-drug conjugates (ADCs) for targeted cancer therapies. Its primary focus is on creating novel drugs that combine the specificit..
>Volltext.. |
| 120.79 Mio. EUR |
| 147.4 Mio. EUR |
| 3.29 Mio. EUR |
| -41.39 Mio. EUR |
| -41.48 Mio. EUR |
| -0.89 EUR |
| 36.61 Mio. EUR |
| 9.46 Mio. EUR |
| -29.88 Mio. EUR |
| 1.03 |
| -53.03% |
| -95.05% |
| - |
| - |
| - |
| - |
| HEIDELBERG PHARMA, WILEX |
| 15.06.26 |
|
||||
|
||||
|
||||
|
||||
|